肺腺癌分子生物标志物的研究进展  

Research progress on molecular biomarkers of lung adenocarcinomas

作　　者：陈璐[1,3] 李长天 刘艳丽 虎维东 CHEN Lu;LI Changtian;LIU Yanli(First School of Clinical Medical,Gansu University of Chinese Medicine,Gansu,Lanzhou 730000,China)

机构地区：[1]甘肃中医药大学第一临床医学院,兰州市730000 [2]甘肃中医药大学基础医学院 [3]甘肃省肿瘤医院放射科 [4]甘肃省人民医院呼吸科

出　　处：《河北医药》2024年第24期3795-3800,共6页Hebei Medical Journal

基　　金：甘肃省自然科学基金资助项目(编号:21JR7RA595)。

摘　　要：肺癌是全球癌症相关死亡的头号病因,而肺腺癌是最常见的肺癌类型,且发病隐秘,侵袭性强,严重威胁患者生命健康。分子靶向治疗是肺腺癌患者的最佳治疗策略,该技术的进步取决于致癌的分子基础,并开发能够识别新型生物标志物的生物学平台。通过对检测肺腺癌分子标志物的技术和它们在肺腺癌发生发展中的作用机制,以及针对这些标志物提出的治疗策略进行综述,为肺腺癌的临床诊断和治疗提供思路。Lung cancer is the leading cause of cancer-related deaths worldwide.Lung adenocarcinomas,with a hidden onset and strong invasiveness,are the most common type of lung cancers that pose a serious threat to lives and health.Molecular targeted therapy is the optimal therapeutic strategy for lung adenocarcinomas relying on the molecular basis of carcinogenesis and development of biological platforms to recognize new biomarkers.In this paper,we reviewed the existing techniques for detecting molecular markers of lung adenocarcinomas and their mechanisms of action in the occurrence and development of lung adenocarcinomas,and therapeutic strategies based on these markers,aiming to provide ideas for the clinical diagnosis and treatment of lung adenocarcinomas.

关 键 词：肺腺癌 生物标志物 靶向治疗 分子机制 非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]